CTLA4 and cancer: ICIs, such as those targeting the PD-1/PDL-1 or CTLA-4 interactions, have shown a high degree of clinical efficacy as single agent therapies in non-small cell lung cancer and melanoma, and the list of cancer subtypes under investigation is rapidly expanding [26].